In addition, hH 2 HR antagonists are used in treating peptic ulcers, gastresophageal reflux disease, and gastrointestinal bleeding. 7, 8 The hH 3 HR antagonists have been proposed for such therapeutic applications as treatment of Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), epilepsy, and obesity. 1 The hH 4 HR has been suggested as an interesting drug target for the therapy of inflammation, allergy, and autoimmune disorders. 9 While hH 1 HR, hH 2 HR, and hH 4 HRs have been successful targets of blockbuster drugs for treating allergic diseases, gastric ulcer, and chronic constipation, the development of hH 3 HR ligands still lags on their way to market, at least partly because of problems with selectivity. Thus, we decided to focus on developing an understanding of how to make ligands selective for hH 3 HR.
The Results and Discussion Section describes the prediction of 3D structures for all four subtypes (H 1 , H 2 , H 3 , and H 4 ) of hHRs, using the GEnSeMBLE (GPCR ensemble of structures in Received: September 14, 2011 ABSTRACT: Histamine receptors (HRs) are excellent drug targets for the treatment of diseases, such as schizophrenia, psychosis, depression, migraine, allergies, asthma, ulcers, and hypertension. Among them, the human H 3 histamine receptor (hH 3 HR) antagonists have been proposed for specific therapeutic applications, including treatment of Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), epilepsy, and obesity. 1 However, many of these drug candidates cause undesired side effects through the cross-reactivity with other histamine receptor subtypes. In order to develop improved selectivity and activity for such treatments, it would be useful to have the three-dimensional structures for all four HRs. We report here the predicted structures of four HR subtypes (H 1 , H 2 , H 3 , and H 4 ) using the GEnSeMBLE (GPCR ensemble of structures in membrane bilayer environment) Monte Carlo protocol, 2 sampling ∼35 million combinations of helix packings to predict the 10 most stable packings for each of the four subtypes. Then we used these 10 best protein structures with the DarwinDock Monte Carlo protocol to sample ∼50 000 Â 10 20 poses to predict the optimum ligandÀprotein structures for various agonists and antagonists. We find that E206 5.46 contributes most in binding H 3 selective agonists (5, 6, 7) in agreement with experimental mutation studies. We also find that conserved E5.46/S5.43 in both of hH 3 HR and hH 4 HR are involved in H 3 / H 4 subtype selectivity. In addition, we find that M378 6 .55 in hH 3 HR provides additional hydrophobic interactions different from hH 4 HR (the corresponding amino acid of T323 6 .55 in hH 4 HR) to provide additional subtype bias. From these studies, we developed a pharmacophore model based on our predictions for known hH 3 HR selective antagonists in clinical study [ABT-239 1, GSK-189,254 2, PF-3654746 3, and BF2.649 (tiprolisant) 4] that suggests critical selectivity directing elements are: the basic proton interacting with D114 3.32 , the spacer, the aromatic ring substituted with the hydrophilic or lipophilic groups interacting with lipophilic pockets in transmembranes (TMs) 3À5À6 and the aliphatic ring located in TMs 2À3À7. These 3D structures for all four HRs should help guide the rational design of novel drugs for the subtype selective antagonists and agonists with reduced side effects. The Methods Section extends the comparison of the 3D structure of our predicted structure with the recently reported 3.1 Å crystal structure of the hH 1 HRÀT4-lysozyme fusion protein (H1RÀT4L) complex with doxepin.
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11 Since we predicted the 3D structure of all HRs when no X-ray structure of the HRs was available, this comparison will validate our methods. The 1.3 Å root mean squared deviation (RMSD) in TM between two structures reveals our atomic details of binding site, and the model will be highly useful for guiding rational design of ligands with high H 3 HR selectivity.
' RESULTS AND DISCUSSION GEnSeMBLE Predictions of Apoprotein Structures for All Four HRs. The seven TM domains of four hHRs in Figure 1 were predicted by PredicTM which combines hydrophobicity analysis and multiple sequence alignment of sequences using the MAFFT 12 program. Hydrophobic profile in the multiple sequence alignment, using the thermodynamic and biological hydrophobic scales from White and von Heijne, 13, 14 shows all hHRs have seven TM characters as shown in GPCRs; hH 2 HR has a shorter intracellular three loop compared to other subtypes. Figure 2 shows the final TM regions and multiple alignments of all HRs from PredicTM. All TM regions of 4 subtypes applied by capping rules are in good agreement within 1À5 residue difference at the terminal end.
The GEnSeMBLE method 2 was used to predict the 3D structure of all 4 HRs before the X-ray structure of the H 1 HR was reported.
11 In GEnSeMBLE we start with some template structures and consider 12 rotations (30°pitch) about the helix axis for each of the 7 TM regions, leading to (7) 12 ∼35 million packings. We then estimate the energy for all 35 million based on the pairwise interactions of the 12 strongly interacting pairs. In these calculations we start with several experimental and computational templates and finally select those with the best total interaction energies.
However when we started this project X-ray crystal structures were avaible for the human β 2 adrenergic receptor (PDB: 2RH1) 15 and the turkey β 1 adrenergic receptor (PDB: 2VT4). 16 Consequently we deviated from our standard methodology for predicting histamine receptor structures as follows:
First, the TM regions in the two templates were identified and the corresponding regions in the four histamine receptors identified based on the higher sequence homology in the TM regions (Table S1 , Supporting Information). Overviews over which residues are part of the TM region for each of the four HRs are shown in Table S2 , Supporting Information.
Then, each TM was mutated to match the HR of interest and energy-minimized in vacuous. Then the 7 helix bundle was used as input to the BiHelix protocol of GEnSeMBLE 2 in which 144 combinations are considered for each pair each with reoptimized side chains. Here, each of the seven TMs was rotated systematically (90°using a 15°sampling interval, leading to structures for the packed bundle. Then we superimposed the BiHelix energies to estimate the 1000 energetically most favored 7 TM helix bundles. These bundles were then built, the side-chains reoptimized, using the SCREAM procedure, 17 and the total energies were calculated using both the standard charged model (where Asp, Glu, Lys, Arg have net charges) and the neutral model we have developed.
18 From these 1000 we collected the Journal of Chemical Information and Modeling ARTICLE best 10 in Table 1 for each combination of HR and template. These results make it clear that for hH 1 HR and hH 3 HR the structures derived from the human β 2 adrenergic receptor were significantly more favorable energetically than models derived from the turkey β 1 adrenergic receptor. In contrast, for hH 2 HR and hH 4 HR the structures derived from the turkey β 1 adrenergic receptor were most favorable. For these best 10 structures, we examine new configurations including rotations of (15°for TM3, À15°, (30, 45°for TM4, and 15°for TM5. We found that the structure derived directly from the initial helix bundle (i.e., with η = 0°for all 7 helices) was not unreasonably high in energy. This preference for structures near 0°supports the applicability of these two X-ray crystal structures as a reasonable starting point for the BiHelix sampling. Indeed, the top-scoring structures for all four HRs differed in the rotation of only a single one of the seven TMs. For hH 3 HR, the top-scoring model had a À30°rotation of TM4 (human β 2 adrenergic receptor as template), whereas for hH 1 HR the topscoring model had a +15°rotation of TM4 (human β 2 adrenergic receptor as template). Moreover for hH 2 HR the top-scoring model had a À15°rotation of TM4 (turkey β 1 adrenergic receptor as template), while for hH 4 HR the top-scoring model had a +15°rotation of TM5 (turkey β 1 adrenergic receptor as template).
Compared with hH 1 HR (20.90% in overall, 32.15% in TM) and hH 2 HR (17.30% in overall, 33.08 in TM) with low sequence identity in Table S1 in Supporting Information, hH 4 HR has a sequence identity of 34.83% to hH 3 HR and 54.84% in TM regions. Many compounds with reported affinity for hH 3 HR also have affinity for hH 4 HR. Compounds like clozapine and clobenpropit behave as partial agonists at hH 4 HR and as antagonists at hH 3 HR, showing some functional selectivity. 19 Many drug candidates cause undesired side effects through their crossreactivity. To develop improved selectivity and activity for such treatments, we use the 10 most stable three-dimensional structures for all four HRs.
Predicted Structures for Ligands Binding to All Four HRs. First generation hH 3 HR antagonists were monoalkyl-substituted imidazole-based derivatives like thioperamide, clobenpropit, or ciproxifan. 20 Potent stimulation of hH 3 HR has been observed by imidazole derivatives only. Claimed interaction potential to cytochrome P450 (CYP) isozymes caused by the imidazole moiety related to elements of the porphyrine cycle and sometimes complex pharmacological behavior led to imidazole Figure 2 . Alignments of the four HR subtypes, H 1 , H 2 , H 3 , and H 4 from the PredicTM method. The predicted TM regions from PredicTM are displayed in colored boxes (TM1 in purple, TM2 in blue, TM3 in cyan, TM4 in green, TM5 in yellow, TM6 in orange, TM7 in red). Highly conserved residues in family A GPCRs are shown in red in TM1À6 and white in TM7. Variable amino acids among the four subtypes in the upper TM regions are marked with red asterisks, and subtype selective residues predicted from the cavity analysis are boxed. We use BallesterosÀWeinstein numbering consisting of the TM helix number followed by residue number relative to the highly conserved residue in the helix, numbered as 50. H-bonding is indicated by arrows, and subtype selective residues are shown in red.
replacements. A general pharmacophore element of these nonimidazole derivatives has been described which is nowadays shown in numerous variations and combinations: A basic moiety is linked by a spacer to a central, mostly aromatic core structure which then is connected to further affinity enhancing elements, e.g., another basic moiety or hydrophilic/lipophilic groups or a combination thereof. a a All 1000 models from CombiHelix were selected for neutralization by their charge total energy (E) score (ChargeTot: kcal/mol). The final 100 models were ordered by neutral total E (NeutTot: kcal/mol). The case with η = 0°for all 7 helices is represented in italic, and the best E is shown in bold. CIH is charge interhelical energy, CTot is charge total energy, NIH is neutral interhelical energy, and NTot is neutral total energy. *The case with η = 0°for all 7 helices is ranked as 12 (E: 43.6 kcal/mol) in hH 3 HR-β2 and 34 in hH 4 HR-β1 (E: 298.9 kcal/mol), respectively. Among these, we selected structurally known compounds (structures shown in Chart 1) like ABT-239 1 (pK i : 9.35 at hH 3 HR), for cognitive disorder (Phase I), 23 GSK-189254A 2 (pK i : 9.59 at hH 3 HR) for dementia, narcolepsy, and schizophrenia (Phase I), 24 PF-3654746 3 (pK i : 8.49 at hH 3 HR) for allergic rhinitis (Phase II), and BF2.649 4 (tiprolisant, pK i : 8.3 at hH 3 HR) for central nervous system disease: hypersommina and narcolepsy (Phase II) 25 for docking studies. As summarized in the Methods Section, the DarwinDock method for predicting ligand binding sites starts by sampling the full protein to locate putative binding regions and then aims at sampling a complete set of ligand conformation (∼20) for each; of which we sample a complete set of poses (∼50 000) from which we select the best poses using the total binding energy, E.
Endogenous Agonist Histamine. We docked histamine, the endogenous agonist 5, to the lowest E predicted structure of hH 3 26 Histamine has similar interactions in hH 4 HR with the main interaction at D114 3.32 /E206 5.46 . 27, 28 Supporting this, the Ala mutation of E206 5.46 , which was the most major contributing residue in the cavity analysis (Table 2) , shows dramatic loss of agonist with more than 2000-fold decrease. In addition, T204A
5.44 and A202Q 5.42 mutants display substantial decrease of histamine binding with 5.7-and 4.2-fold decrease compared with the wildtype, respectively. 26 In the neutral system of histamine-hH 3 HR, we find that the deprotonated nitrogen atom of the histamine interacts with the protonated D114 3.32 , while the protonated E206 5.46 also H-bonds with the ε-NH atom in the imidazole ring of histamine, as shown in Figure 3 . An additional hydrophobic interaction occurs at F207 Figure 4) . The result is a dramatic decrease in binding affinity (cavity sum = À18.07 for (R)-α-methyl histamine 6 vs À8.39 for (S)-α-methyl histamine 7) in agreement with the dramatically decreased experimental binding affinity of (S)-α-methyl Figure 3 . Predicted best models of the endogenous agonist histamine 5 bound to hH 3 HR. The H-bonding is represented by the arrows with the distance between the donor and the acceptor. The number with residue is from the order of unified cavity E in Table 2 . Schematic structure of the predicted binding sites is displayed in the bottom figure. 
ARTICLE histamine 7 at hH 3 HR (pK i at hH 3 HR: 8.2 for 6 vs 7.2 for 7).
29
The cavity analysis of the H 3 selective agonists (5, 6, 7) suggests the major contributing amino acid is E206 5.46 (Tables 2 and 3 ). These docking results are in good agreement with the current mutational study. The most pronounced reduction in potency and affinity of the agonists was seen with the mutation of E206 5.46 . 26 Thus the stereoselectivity of the methylated histamine derivatives is explained by these docking studies. The result agrees with experimental observations that the methylated histamine derivative, (R)-α-methylhistamine, is the more selective and the potent hH 3 HR agonist. The (S)-stereoisomer is about 100 times less potent than the (R)-isomer. 29 Docking of hH 3 HR Selective Antagonist 8, Clobenpropit, at All Four HRs and Further SAR Studies. Antagonist docking started from the assumption that classical H 3 antagonists, such as monoalkyl-substituted imidazole-based derivatives, would share the interaction between their imidazole ring and E206 5.46 , as shown in the endogenous agonist, histamine 5. This hypothesis is based on the partial structural similarity between histamine and imidazole-containing H 3 antagonists (i.e., the imidazole ring, the spacer, and the basic or polar portion).
We docked hH 3 HR selective antagonist 8, clobenpropit, to the lowest E predicted structures of all four hHRs of 5.46 . The para-chloro-benzyl group of clobenpropit 8 is surrounded by hydrophobic residues, L401 7.42 and W402 7.43 , as shown in Figure 5 . (S)-α-methyl histamine with ∼100-fold less binding affinity displayed unfavorable interaction at Y115 with α-methyl groups in red arrow. The number with residue is from the order of unified cavity E in Table 3 . Schematic structure of the predicted binding sites is displayed in the bottom figure.
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To understand subtype selectivity, we matched the predicted best binding pose of the highly H 3 -selective ligand clobenpropit 8 at hH 3 Figure 2 ). Both of two subtype variable residues in hH 1 HR and hH 2 HR show weakened interactions in the cavity in Table 4 and Figure 6 , resulting in a 2.2À2.4 kcal/mol favorable interaction in hH 3 HR. However, the similar interaction is shown at these two conserved residues of hH 4 HR. Thus, the final cavity sum is a substantial decrease in binding affinity (cavity sum = À34.11 in hH 1 HR, À33.77 in hH 2 HR) in agreement with the dramatically decreased experimental binding affinity at hH 1 HR (pK i : 5.6) and hH 2 HR (pK i : 5.2). The final cavity sum with the weakened binding affinity at hH 4 HR (pK i : 7.4) is a À35.12 kcal/mol compared with the cavity sum of hH 3 HR (pK i : 9.4), À36.94 kcal/mol. Thus, this predicted binding energy is consistent with the experimental binding affinity of H 3 subtype selective clobenpropit 8. 30 The predicted structures were ordered by experimental binding affinity, including unified cavity energy (UniCav E) in Table 5 in all subtypes of hHRs. Furthermore, all scoring energies at all HRs parallel with theirs experimental binding affinities with the r 2 values (correlation coefficients) of 0.67 to 0.99 ( Figure 7) .
For further SAR studies, we included four more antagonists, ciproxifan 9, thioperamide 10, A-304121 11, and A-317920 12 in the same literature. 30 Predicted binding cavity energies for eight models in good agreement with experimental relative binding constants (r 2 = 0.65 for all 8 and r 2 = 0.93 for 6 excluding the flexible ligands, A-304121 11, and A-317920 12, which include more than 10 rotatable bonds in their structures in Figure 7 ). All of them share the same binding site with major anchoring site at D114 3.32 in Figure 6 . Based on the docking studies of the subtype selective antagonist clobenpropit 8, we suggest that E5.46/S5.43 in hH 3 HR and hH 4 HR are involved in additional H-bonding In the BallesterosÀWeinstein numbering, the most conserved residue in each of the seven TM domains is taken as the reference and numbered as 50. This residue is designated x.50 where x is the number of the TM helix.
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interactions with the terminal imidazole group in the monoalkyl-substituted imidazole-based derivatives, however these interactions are lost in hH 1 HR and hH 2 HR, as shown in Figure 6 . Supporting this, sequence alignments show that TM5 of the hHRs is poorly conserved, suggesting a potential differences in the mechanism in which histamine binds to the hH 3 HR. For the difference between hH 3 HR and hH 4 HR, M378 6 .55 in hH 3 HR (which is the corresponding amino acid of T323 6 .55 in hH 4 HR) stabilizes through additional hydrophobic interactions (À1.28 kcal/mol at M378 6.55 vs À0.41 kcal/mol at T323 6.55 ). Thus this predicted structure explains the increase of H 3 selectivity for clobenpropit 8 at hH 3 HR over the other three subtypes.
In addition, scoring energy of hH 3 HR selective antagonist clobenpropit for all HRs correlates with the observed experimental binding affinities with r 2 values (correlation coefficients) of 0.69À0.98.
Docking of Structurally Known hH 3 HR Selective Antagonists in Clinical Studies. Docking studies were also carried out using structurally known hH 3 HR selective antagonists in clinical trials, ABT-239 1, GSK-189,254 2, PF-3654746 3, and BF2.649 4. To develop a general pharmacophore model for these nonimidazole derivatives with hH 3 HR selectivity, we selected structurally known hH 3 HR targeting drugs in phase I or II preclinical studies, ABT-239 1 (pK i : 9.35), GSK-189254A 2 (pK i : 9.59), PF-3654746 3 (pK i : 8.49), and BF2.649 4 (tiprolisant, pK i : 8.3) for further docking studies.
As shown in Figure 8 , the binding sites of four antagonists overlap, as expected. A central basic moiety shows common H-bonding at D114 3.32 . An aromatic core structure leads to further affinity enhancing elements, e.g., hydrophilic/lipophilic groups are surrounded by hydrophobic cavity in TMs 3À5À6 region. The aliphatic ring including a protonated nitrogen is surrounded by another hydrophobic cavity in TMs 2À3À7. GSK-189254A 2 shows an extra H-bond at S203 5.43 with the nitrogen atom in the pyridine ring. PF-3654746 3 also forms additional H-bonding interactions among the terminal amino group, Y194
5.34 and E206 5.46 , and between F substituent and Y374 6 .51 . All hH 3 HR selective antagonists could be mutually superposed following a common pharmacophore model with similar arrangements at the same binding site. The proposed pharmacophore model suggests the basic proton interacting with D114 3.32 , the spacer, the aromatic ring substituted with the hydrophilic or lipophilic groups interacting with lipophilic pockets in TMs 3À5À6 and the aliphatic ring located in TMs 2À3À7. This model is in good agreement with the current generally accepted model; a basic amine motif separated by several atoms from the central, typically hydrophobic, core, which is joined on the other side by a structurally variable region in the form of another basic amine or a polar, nonbasic arrangement (e.g., amide). 5 Structure Comparison of Predicted Structure and the Experimental X-ray Structure of the hH 1 HR (PDB ID: 3RZE). 11 Compared to the crystal structure of the hH 1 HR, the RMSD of the predicted hH 1 HR structure generated by our GEnSeM-BLE method showed 1.33 Å RMSD in whole TMs, as shown in Table 6 . There were also no big differences with other subtypes in the average backbone RMSD of TM helices with less than 1.64 Å for all three hH 2 HR (1.64 Å), hH 3 HR (1.33 Å), and hH 4 HR (1.60 Å). The most similar structure of hH 1 HR is hH 3 HR with 0.04 Å. Among TMs major structural deviations are shown at the TMs 1 and 5 with 0.85 and 0.84 Å RMSD, respectively.
The recent availability of GPCR crystal structures provides some mechanistic insights into both the inactive and active forms, which should be useful in designing ligands for therapeutic applications. These results show that the seven-helix TM topology of these receptors can exhibit multiple conformations with variations in interhelical orientations, which in turn can change the binding site and energy of various ligands. These multiple conformations are observed both for a given GPCR in different functional forms (e.g., inactive vs active) and across different GPCRs. The conformational variations already found in the crystallized GPCRs strongly suggest that homology models based on a single template would not be sufficiently flexible to Figure 5 . Predicted best models of the H 3 selective antagonist clobenpropit 8 bound to the hH 3 HR. The H-bonding is represented by the arrows between the donor and the acceptor. The number with residue is from the order of unified cavity E in Table 5 . Schematic structure of the predicted binding sites is displayed in the bottom figure.
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describe the multiple functional forms of a receptor and would be unlikely to predict the important configurations of other GPCRs.
The GEnSeMBLE method applied in this paper was developed to enable exhaustive sampling of the conformational space to sample the variety of packings explored by receptors. We expect that this procedure dramatically increases the likelihood of predicting accurate structures for functionally distinct conformations of a GPCR and for predicting the structures of other more distant GPCRs. As additional GPCRs are crystallized to more fully cover both sequence space and function space (through G protein or β arrestin coupled pathways), such de novo prediction methods should increase in accuracy because of additional templates to initiate the process. Our results indicate that starting with a template for a crystal for one subtype of a GPCR, we can obtain accurate structures for the other subtypes. Also given a crystal structure of one GPCR, we can obtain accurate structures for other GPCRs that are within ∼30% sequence identify for the TM regions. Figure 6 . Predicted best models of the H 3 selective antagonist clobenpropit 8 bound to hH 1 HR, hH 2 HR, hH 3 HR, hH 4 HR and other antagonists, ciproxifan 9, thioperamide 10, A-304121 11, and A-317920 12 at hH 3 HR. H-bonding is indicated by red dots, and subtype selective residues are shown in red. Figure 7 . Predicted binding energies (kcal/mol) to the H 3 selective antagonist clobenpropit 8 bound to hH 1 HR, hH 2 HR, hH 3 HR, hH 4 HR and other antagonists, ciproxifan 9, thioperamide 10, A-304121 11, and A-317920 12 at hH 3 HR listed in Table 5 compared with the experimental binding constants (pK i ). The dotted line shows the fit without two outliers, 11 and 12, which is much more flexible than the others.
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We docked several H 3 selective ligands to all four subtypes to determine the critical components defining H 3 subtype selectivity with respect to the other three subtypes obtained. Our predictions of the best conformations of the histamine at H 1 , H 2 , H 3 , and H 4 receptors subtypes lead to several conclusions: (1) The largest contribution to binding of the H 3 selective agonists (5, 6, 7) is E206 5.46 in good agreement with the experimental mutational studies; (2) We find that the conserved E5.46/S5.43 in both of hH 3 HR and hH 4 HR are involved in H 3 / H 4 subtype selectivity through additional H-bonding with the terminal imidazole group in the monoalkyl-substituted imidazole-based derivatives but loss of these interactions in hH 1 HR and hH 2 HR. In addition, M378 6 .55 in hH 3 HR is another subtype selective residue provides additional hydrophobic stabilization different from hH 4 HR (the corresponding amino acid of T323 6.55 in hH 4 HR); (3) Our proposed pharmacophore model suggests that the residues important for selectivity to hH 3 HR are: the basic proton interacting with D114 3.32 , the spacer, the aromatic ring substituted with the hydrophilic or lipophilic groups interacting with lipophilic pockets in TMs 3À5À6, and the aliphatic ring located in TMs 2À3À7.
We expect our predicted 3D structures for all four HRs will help guide the rational design of novel H 3 subtype selective antagonists and agonists with reduced side effects. The excellent agreement with current experimental studies, particularly the understanding of H 3 subtype selectivity indicates that computationally derived structures of GPCRs can be sufficiently accurate to develop subtype selective drug to minimize side effects.
' METHODS
We used the GEnSeMBLE method 2 to predict the 3D structures for the various conformations needed to understand the function of GPCRs and help design new ligands. GEnSeMBLE provides a very complete sampling (millions to quadrillions) over possible rotations and tilts, leading to a ensemble of lowlying structures expected to include those conformations energetically accessible for binding of ligands. This replaces our earlier MembStruk method. 31 We use the DarwinDock to predict the binding sites of ligands to the GPCRs. DarwinDock samples ∼20 conformations for ∼50 000 poses expanding the predicted binding sites, which we consider to be a very complete sampling. DarwinDock replaces our earlier HierDock 6 and MSCDock 32 methods, providing a much more complete sampling of possible poses. These earlier methods were validated by a series of applications to various GPCRs: human D 2 dopamine receptor (DR), 33 human β 2 adrenergic receptor, 34, 35 human M 1 muscarinic receptor, 36 human Chemokine (CÀC) motif receptor 1 (CCR1), 37 mouse MrgC11 (mas related gene) for the molluscan peptide FMRFamide (FMRFa), 38, 39 human prostanoid DP receptor, 40 human Serotonin 2C, 18 and human A 2A adenosine 41 receptor.
GEnSeMBLE
41
. The structure prediction methodology has been described previously 41 so it will only be briefly summarized here: (1) PredicTM: This uses multiple sequence alignment to predict the TM regions for membrane protein. proper kinks (may be caused by Prolines) using molecular dynamics. However when closely related X-ray structures are available (as for the HRs), we find that homology helices often provide better helix shapes. 
Journal of Chemical Information and Modeling
ARTICLE
helix bundle for each of these 1000 and optimize the side chains for each using SCREAM. From this 1000, we select an ensemble of ∼10 lowest energy structures, each of which is used in docking of various ligands. The Dreiding D3 force field (D3FF) 42 was used throughout, wherever energies were evaluated.
Ligand Docking. DarwinDock was used to dock several ligands to each of the lowest 10 predicted structures of all 4 hHRs from BiHelix. The starting structure and charges of the ligands in Chart 1 were calculated using density functional theory (B3LYP with the 6-311G** basis set).
Starting from the X-ray structure of histamine, we rotated the torsion angles NÀC al ÀC al ÀC ar by 60°increments to generate 6 conformations. These were generated with the Maestro software and minimized with the D3FF. The final docked structure with the best binding E from all ligand conformations was selected.
Scanning the Receptor for Potential Binding Regions. Starting with the predicted structure, we predicted putative ligands binding regions as follows: We first alanized the entire protein (replacing the 6 hydrophobic residues, I, L, V, F, Y, and W with A) and scanned for potential binding regions with no assumption about the binding site. The entire molecular surface of the predicted structure was mapped with spheres representing the empty volume of the protein (currently using the Sphgen procedure in DOCK4.0 suite of programs). The entire set of protein spheres was partitioned into ∼30À50 overlapping cubes of 10À14 Å sides. We then generated 1000 poses for each of these 30À50 regions. These results are compared to select the most promising two or three putative binding regions.
DarwinDock. For each ligand conformation, we used DarwinDock to generate iteratively ∼50 000 poses spanning the putative binding regions of the bulky residue-alanized protein. These poses are partitioned into ∼1200 to ∼200 family head Voronai-like families based on RMSD, and then calculated the energies of the family heads and selected the top 10% ordered by total energy. Next we calculated the binding energy for all the family members of these top 10% family and selected the lowest energy 100 structures for further optimization. For each of these 100, we dealanize the protein side chains (using SCREAM) to find the optimum side chains for each of the best 100 poses. Then we neutralize the protein and the ligand by transferring protons appropriately within salt bridges and protonating or deprotonating exterior ligands, followed by further full geometry minimization.
DarwinDock has been validated for a number of X-ray cocrystals including 3 crystal structures of ligand/GPCR complexes: human β 2 -adrenergic receptor (0.4 Å RMSD), 15 human AA 2A R (0.8 Å RMSD), 43 and turkey β 1 -adrenergic receptor (0.1 Å RMSD). 16 This shows that DarwinDock can accurately identify ligand binding sites in proteins, which can then be used to optimize the ligands with desirable properties.
Neutralization for Scoring E. Quantum mechanics (QM) calculations show that for an effective dielectric constant below 8, the extra proton on a Lys or Arg transfers back to the negative carboxylate of an Asp or Glu. Thus we expect that buried salt bridges will have neutral residues. We find that use of these neutral residue charges for the protein and the ligand improves the accuracy for comparing different docked structures. Of course the final bond energy relative to ligand in the solvent and binding site exposed to solvent must be corrected by the effective pK A of the ligand and of the exposed Lys, Arg, Glu, and Asp. For example, if the pK A of a carboxylate is 4.5 and the solvent is taken to have a pH of 7.4, we must correct by 2.9 Â 1.38 kcal/mol.
For external residues not involved in binding, we also find it is expected to neutralize the external residues exposed to solvent or membrane. Here the issue is that the force fields commonly used in molecular dynamic calculations involve fixed charges, usually based on QM. In reality any net partial charges are shielded by the dielectric polarization of the surrounding protein and solvent, so that there is negligible effect beyond 10 Å. However with fixed charges, the electrostatic interaction energy between two point charges separated by 10 Å is 33 kcal/mol. The result is that small changes in geometries of charged ligands far from the binding site can lead to large differential binding energies, even 10À30 kcal/ mol. We find that neutralizing these exposed residues removes the sensitivity to details of the distances of charged residues (and counterions) remote from the active site. This neutralization leads to differential binding energies that are dominated by the local cavity interactions and leads to much smaller solvation energies.
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' ASSOCIATED CONTENT b S Supporting Information. Sequence identities of four human HRs and X-ray structures, tβ 1 AR, hβ 2 AR, hAA 2A R, and bovine rhodopsin (Table S1 ); overview of residue numbering for the TM regions in each of the four HRs based on homology to tβ 1 AR and human β 2 adrenergic receptor (Table S2 ). This information is available free of charge via the Internet at http://pubs.acs.org. ' REFERENCES
